Friday, 2 June 2017

In-Depth Research on Type 2 Diabetes - Pipeline Review, H1 2017

Type 2 Diabetes - Pipeline Review, H1 2017 is a new market research publication announced by Reportstack. This report provides an overview of the Type 2 Diabetes (Metabolic Disorders) pipeline landscape.
Type 2 diabetes is a chronic condition and is the most common form of diabetes. High levels of glucose are a characteristic feature. The body might become resistant to insulin or may not produce enough amounts. Due to abnormal insulin functioning, glucose is concentrated in the blood leading to elevated levels and hence causing type 2 diabetes. Symptoms include fatigue, weight issues, vision deficits and various other effects. Risk factors include family history, age, obesity, physical inactivity and high blood pressure. This condition is handled by lifestyle alterations and regular medications.
Complete report available @ Type 2 Diabetes - Pipeline Review, H1 2017
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Type 2 Diabetes - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Type 2 Diabetes (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Type 2 Diabetes (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Type 2 Diabetes and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 14, 1, 25, 68, 64, 5, 250, 75 and 6 respectively. Similarly, the Universities portfolio in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 1, 62 and 22 molecules, respectively.
Type 2 Diabetes (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Type 2 Diabetes (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Type 2 Diabetes (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Type 2 Diabetes (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Type 2 Diabetes (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Type 2 Diabetes (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Type 2 Diabetes (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
4P Therapeutics LLC Addex Therapeutics Ltd Adocia Advinus Therapeutics Ltd Aegis Therapeutics LLC AFFiRiS AG Alize Pharma SAS Allergan Plc Alteogen Inc Amarantus Bioscience Holdings Inc Amgen Inc Anchor Therapeutics Inc AntriaBio Inc Aphios Corp Araim Pharmaceuticals Inc Arena Pharmaceuticals Inc Arisaph Pharmaceuticals Inc ArisGen SA Astellas Pharma Inc AstraZeneca Plc AusBio Ltd Avadel Pharmaceuticals Plc Bayer AG Beta-Cell NV Betagenon AB Betta Pharmaceuticals Co Ltd Biocon Ltd BioLingus AG BioRestorative Therapies Inc Biozeus Biscayne Pharmaceuticals Inc Boehringer Ingelheim GmbH Boston Therapeutics Inc Braasch Biotech LLC Bristol-Myers Squibb Company C4X Discovery Holdings PLC Cadila Pharmaceuticals Ltd Cardax Inc Carmot Therapeutics Inc Celon Pharma SA Chipscreen Biosciences Ltd Chong Kun Dang Pharmaceutical Corp CJ HealthCare Corp CohBar Inc Concenter BioPharma Silkim Ltd ConjuChem LLC Connexios Life Sciences Pvt Ltd ConSynance Therapeutics Inc Corium International Inc CSL Ltd CureDM Inc CymaBay Therapeutics Inc Daewoong Pharmaceutical Co Ltd Daiichi Sankyo Company Ltd Dance Biopharm Inc Delpor Inc Diabetology (Products) Ltd DiaMedica Therapeutics Inc,etc.
Debora White
Manager - Marketing
Ph: +1-888-789-6604
ReportstackMarket Research


Post a Comment

Subscribe to Post Comments [Atom]

<< Home